Table 2

Dose of anti-IL drug, acute phase reactants, physician assessment of disease and response to treatment at last follow-up on treatment with Canakinumab and at the moment of anakinra withdrawal

Last follow-up on canakinumab

Last follow-up on anakinra


Patient

number

Dose, mg (mg/Kg)/frequency

CRP, mg/dl

SAA, mg/l

Clinical assessment

Response

Dose. mg (mg/kg)/frequency

CRP, mg/dl

SAA mg/l

Clinical assessment

Response


11

300 (4.30)/5 wks

1.17

29.9

mild

partial

75 (1.30)/day

0.61

25.0

absent

partial

21

150 (4.00)/6 wks

1.18

ND

moderate

inadequate

75 (2.00)/day

neg

18.0

absent

partial

31

300 (5.90)/6 wks

2.67

18.1

absent

partial

100 (1.80)/day

0.47

7.50

absent

partial

41

150 (2.80)/6 wks

neg

neg

absent

complete

100 (2.00)/day

neg

neg

minimal

complete

52

78 (2.00)/8 wks

neg

neg

absent

complete

55 (2.00)/day

neg

neg

minimal

complete

62

300 (3.75)/7 wks

0.57

6.5

absent

partial

100 (1.16)/day

0.63

neg

mild

partial

71

300 (3.70)/4 wks

1.20

64.0

mild

partial

100 (1.30)/day

0.73

neg

absent

partial

82

150 (2.30)/6 wks

neg

neg

absent

complete

ND

ND

ND

ND

ND

92

150 (2.40)/8 wks

neg

neg

absent

complete

50 (1.00)/day

neg

neg

absent

complete

102

100 (2.00)/8 wks

neg

neg

absent

complete

20 (0.66)/day

neg

neg

absent

complete

111

60 (2.00)/7 wks

neg

neg

absent

complete

23 (1.00)/day

neg

13.2

mild

partial

121

150 (2.00)/8 wks

neg

neg

absent

complete

55 (1.00)/day

neg

neg

absent

complete

132

78 (2.00)/10 wks

neg

neg

absent

complete

38 (1.00)/day

neg

neg

absent

complete


1Patients with the chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2patients with the Muckle-Wells syndrome (MWS) and MWS/CINCA phenotype; CRP, C reactive protein; SAA, serum amyloid A; neg, negative; ND, not done.

Caorsi et al. Arthritis Research & Therapy 2013 15:R33   doi:10.1186/ar4184

Open Data